---
title: "Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295011352.md"
description: "The CTIM-76 and CT-202 clinical programs will be given top priority, with the first clinical results anticipated to be available in the second quarter of 2027."
datetime: "2026-08-05T20:17:37.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295011352.md)
  - [en](https://longbridge.com/en/news/295011352.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295011352.md)
---

# Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress

The CTIM-76 and CT-202 clinical programs will be given top priority, with the first clinical results anticipated to be available in the second quarter of 2027.

### Related Stocks

- [CNTX.US](https://longbridge.com/en/quote/CNTX.US.md)

## Related News & Research

- [Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move](https://longbridge.com/en/news/295061614.md)
- [Context Therapeutics Q2 net loss widens on higher R&D costs](https://longbridge.com/en/news/295014877.md)
- [Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study](https://longbridge.com/en/news/289805331.md)
- [CNTX: CTIM-76 achieved a 29% response rate and low-grade CRS in late-line ovarian cancer patients](https://longbridge.com/en/news/289805735.md)
- [Charles Zhu Reiterates Buy on Context Therapeutics, Citing Encouraging CTIM-76 Efficacy, Favorable Safety, and De‑Risked Development Outlook](https://longbridge.com/en/news/289813604.md)